EP1040201A4 - Einkettige monoklonal-antikörper-fusions-agentien die die in vivo transkription regulieren - Google Patents

Einkettige monoklonal-antikörper-fusions-agentien die die in vivo transkription regulieren

Info

Publication number
EP1040201A4
EP1040201A4 EP97949553A EP97949553A EP1040201A4 EP 1040201 A4 EP1040201 A4 EP 1040201A4 EP 97949553 A EP97949553 A EP 97949553A EP 97949553 A EP97949553 A EP 97949553A EP 1040201 A4 EP1040201 A4 EP 1040201A4
Authority
EP
European Patent Office
Prior art keywords
vivo
monoclonal antibody
single chain
antibody fusion
regulate transcription
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97949553A
Other languages
English (en)
French (fr)
Other versions
EP1040201A1 (de
Inventor
James P Hoeffler
Marijane Russell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Technologies Corp
Original Assignee
Invitrogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invitrogen Corp filed Critical Invitrogen Corp
Publication of EP1040201A1 publication Critical patent/EP1040201A1/de
Publication of EP1040201A4 publication Critical patent/EP1040201A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EP97949553A 1997-11-28 1997-11-28 Einkettige monoklonal-antikörper-fusions-agentien die die in vivo transkription regulieren Withdrawn EP1040201A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1997/021407 WO1999028502A1 (en) 1997-11-28 1997-11-28 Single chain monoclonal antibody fusion reagents that regulate transcription in vivo

Publications (2)

Publication Number Publication Date
EP1040201A1 EP1040201A1 (de) 2000-10-04
EP1040201A4 true EP1040201A4 (de) 2001-11-21

Family

ID=22262117

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97949553A Withdrawn EP1040201A4 (de) 1997-11-28 1997-11-28 Einkettige monoklonal-antikörper-fusions-agentien die die in vivo transkription regulieren

Country Status (3)

Country Link
EP (1) EP1040201A4 (de)
AU (1) AU3587599A (de)
WO (1) WO1999028502A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1242457T3 (da) 1999-12-28 2004-12-20 Esbatech Ag Intracellulære antistoffer [intracellulære antistoffer] med defineret struktur, der er stabil i et reducerende miljö, og anvendelse deraf
US6696620B2 (en) 2000-05-02 2004-02-24 Epicyte Pharmaceutical, Inc. Immunoglobulin binding protein arrays in eukaryotic cells
US6406863B1 (en) * 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
US6410246B1 (en) * 2000-06-23 2002-06-25 Genetastix Corporation Highly diverse library of yeast expression vectors
US6410271B1 (en) * 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
US7005503B2 (en) 2002-02-08 2006-02-28 Genetastix Corporation Human monoclonal antibody against coreceptors for human immunodeficiency virus
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
US6610472B1 (en) * 2000-10-31 2003-08-26 Genetastix Corporation Assembly and screening of highly complex and fully human antibody repertoire in yeast
US20030059834A1 (en) * 2001-02-01 2003-03-27 Chang Nancy T. Methods to generate and identify monoclonal antibodies to a large number of human antigens
ATE434040T1 (de) 2001-10-01 2009-07-15 Dyax Corp Mehrkettige eukaryontische display-vektoren und deren verwendungen
AU2003209059A1 (en) * 2002-02-08 2003-09-02 Genetastix Corporation Human monoclonal antibodies against membrane proteins
DK1506236T3 (da) 2002-05-22 2013-03-04 Esbatech A Novartis Co Llc Immunglobulin-frameworks, der udviser forbedret stabilitet i det intracellulære miljø og fremgangsmåder til identifikation deraf
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
KR101323827B1 (ko) * 2010-01-08 2013-10-31 키스트 유럽 에프게엠베하 강직성척추염 진단용 프라이머 및 이를 이용한 강직성 척추염 진단 방법
EP2593594B1 (de) 2010-07-16 2017-09-27 Adimab, LLC Antikörperbibliotheken
CN108060232A (zh) * 2017-12-13 2018-05-22 安徽师范大学 用于扩增乌龟雄激素受体（AR）基因的RT-qPCR引物和方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0557897A1 (de) * 1992-02-28 1993-09-01 F. Hoffmann-La Roche Ag Antigenbindende Proteine und Verfahren zu ihrer Herstellung
WO1996002561A1 (en) * 1994-07-20 1996-02-01 The General Hospital Corporation Interaction trap systems for detecting protein interactions
WO1996030512A1 (fr) * 1995-03-31 1996-10-03 Rhone-Poulenc Rorer S.A. Systeme d'expression conditionnel
WO2000054057A1 (en) * 1999-03-10 2000-09-14 Medical Research Council Selection of intracellular immunoglobulins
WO2001048017A1 (en) * 1999-12-28 2001-07-05 Esbatech Ag Intrabodies with defined framework that is stable in a reducing environment and applications thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525491A (en) * 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
WO1994021294A1 (en) * 1993-03-19 1994-09-29 Bigner Darell D Method of treating tumors with antibodies
US5610013A (en) * 1993-07-22 1997-03-11 Ludwig Institute For Cancer Research Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors
US5658763A (en) * 1993-10-25 1997-08-19 Creative Biomolecules, Inc. Methods and compositions for high protein production from non-native DNA

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0557897A1 (de) * 1992-02-28 1993-09-01 F. Hoffmann-La Roche Ag Antigenbindende Proteine und Verfahren zu ihrer Herstellung
WO1996002561A1 (en) * 1994-07-20 1996-02-01 The General Hospital Corporation Interaction trap systems for detecting protein interactions
WO1996030512A1 (fr) * 1995-03-31 1996-10-03 Rhone-Poulenc Rorer S.A. Systeme d'expression conditionnel
WO2000054057A1 (en) * 1999-03-10 2000-09-14 Medical Research Council Selection of intracellular immunoglobulins
WO2001048017A1 (en) * 1999-12-28 2001-07-05 Esbatech Ag Intrabodies with defined framework that is stable in a reducing environment and applications thereof

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DE JAEGER GEERT ET AL: "Analysis of the interaction between single-chain variable fragments and their antigen in a reducing intracellular environment using the two-hybrid system", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 467, no. 2-3, 11 February 2000 (2000-02-11), pages 316 - 320, XP002143443, ISSN: 0014-5793 *
GARGANO N ET AL: "FROM PHAGE LIBRARIES TO INTRACELLULAR IMMUNIZATION", INTRACELLULAR ANTIBODIES: DEVELOPMENT AND APPLICATIONS, SPRINGER VERLAG, BERLIN,, DE, 1997, pages 173 - 186, XP000916894 *
HAARD DE H J W ET AL: "SELECTION OF RECOMBINANT, LIBRARY-DERIVED ANTIBODY FRAGMENTS AGAINST P24 FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 DIAGNOSTICS", CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 5, no. 5, September 1998 (1998-09-01), pages 636 - 644, XP000939091, ISSN: 1071-412X *
MARASCO W A: "Intracellular antibodies (intrabodies) as research reagents and therapeutic molecules for gene therapy", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 1, no. 1, 1 May 1995 (1995-05-01), pages 1 - 19, XP004052680, ISSN: 1380-2933 *
MARASCO W: "Intrabodies: turning the humoral immune system outside in for intracellular immunization", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 4, no. 1, January 1997 (1997-01-01), pages 11 - 15, XP002097642, ISSN: 0969-7128 *
MHASHILKAR A M ET AL: "Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti- Tat single chain intrabodies", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 14, no. 7, 1995, pages 1542 - 1551, XP002089075, ISSN: 0261-4189 *
PORTNER-TALIANA A ET AL: "In vivo selection of single-chain antibodies using a yeast two-hybrid system", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 238, no. 1-2, April 2000 (2000-04-01), pages 161 - 172, XP004195472, ISSN: 0022-1759 *
See also references of WO9928502A1 *
VISINTIN MICHELA ET AL: "Selection of antibodies for intracellular function using a two-hybrid in vivo system", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 96, no. 21, 12 October 1999 (1999-10-12), pages 11723 - 11728, XP002143442, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO1999028502A1 (en) 1999-06-10
AU3587599A (en) 1999-06-16
EP1040201A1 (de) 2000-10-04

Similar Documents

Publication Publication Date Title
IL128406A0 (en) Monoclonal antibodies
EP1040201A4 (de) Einkettige monoklonal-antikörper-fusions-agentien die die in vivo transkription regulieren
EP1073464A4 (de) Monoklonale antikörper mit verringerter immunisierungsfähigkeit
ZA9510806B (en) Anti-xv-integrin monoclonal antibody
IL136335A0 (en) Monoclonal human natural antibodies
GB9809839D0 (en) Antibody
EP1071458A4 (de) Humanisierter antikörper und dessen verwendungen
HUP0003513A3 (en) Monoclonal antibody inducing apoptosis
EP0870826A4 (de) Neue proteine und gegen diese gerichtete monoklonale antikörper
IL147517A0 (en) Monoclonal antibodies and immunoassay utilizing the same
AU6702998A (en) Anti-alphabeta3 humanized monoclonal antibodies
EP1178829A4 (de) Menschlicher monoklonaler antikörper
AU7072998A (en) Immunoassays using anti-allotypic monoclonal antibodies
ZA973664B (en) Hepatitis b monoclonal antibodies
HUP9800613A3 (en) Humanized antibody against human fas-antigene
HUP9800744A3 (en) Antibodies against fas-antigene
EP0977590A4 (de) Menschliche monoklonale antikörper
GB9818915D0 (en) Antibodies
GB9828700D0 (en) Antibody
GB9718911D0 (en) Monoclonal antibodies
ZA951113B (en) Tumor assosiated monoclonal antibody 123av16
GB9819411D0 (en) Antibodies
EP1106701A4 (de) Monoklonaler antikörper gerichtet gegen aus dem hund stammendes trypsin
EP0984065A4 (de) Modifiziertes, von treponema palladium stammendes proteinantigen.
ZA973643B (en) Metastasis-associated antigen and antibodies thereto.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000518

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB NL

RIN1 Information on inventor provided before grant (corrected)

Inventor name: RUSSELL, MARIJANE

Inventor name: HOEFFLER, JAMES, P.

A4 Supplementary search report drawn up and despatched

Effective date: 20011009

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): DE FR GB NL

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12N 15/10 A, 7C 12N 15/62 B, 7C 07K 16/18 B, 7C 12Q 1/68 B, 7G 01N 33/50 B, 7A 61K 39/395 B, 7G 01N 33/573 B

17Q First examination report despatched

Effective date: 20021210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040902